Cevidoplenib (dimesylate)

Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities[1][2].

Syk

Reference compound

Protein Tyrosine Kinase/RTK

COVID-19-immunoregulation

Inflammation/Immunology

https://www.medchemexpress.com/cevidoplenib-dimesylate.html

98.96

DMSO : 25 mg/mL (ultrasonic)

O=C(C1CC1)C2=CN(C)C3=C2C=C(NC4=NC=CC(N5N=C(C)C(CN6OC[C@@H](O)C6)=C5)=N4)C=C3.CS(=O)(O)=O.CS(=O)(O)=O

665.74

[1]International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 31, No. 4, 2017.|[2]cevidoplenib dimesylate.

Room Temperature

4°C (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-109082A/Cevidoplenib-dimesylate-DataSheet-MedChemExpress.pdf

http://file.medchemexpress.com/batch_PDF/HY-109082A/Cevidoplenib-dimesylate-SDS-MedChemExpress.pdf

Phase 2

2043659-93-2